Body Weight, Aspirin Dose and Pro-resolving Mediators

Completed · Phase 4

Conditions studied: Body Weight

In brief

This study employs a placebo-controlled randomized cross-over design to investigate the impact of body weight and aspirin dose on levels of specialized pro-resolving lipid mediators in blood and neutrophils.

Key facts

Study ID

NCT04697719

Run by

NYU Langone Health

People needed

103

Starts

2021-11-04

Expected to finish

2025-01-29

Last updated by the study team

2026-03-09

Who can join

Age: 40 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age between 40 and 70 years

You may not qualify if…

• Anti-platelet medication use in the past 7 days
• Aspirin intolerance or allergy
• Known bleeding or clotting disorder
• Chronic inflammatory or connective tissue disease
• Immunological deficiency
• Diabetes mellitus
• Prior gastric or bariatric surgery
• Active smoking
• Platelet count <100,000
• Use of omega-3 fatty acid supplementation
• Use of drugs or supplements known to inhibit COX-1/COX-2/lipoxygenases
• Corticosteroid use
• Recent initiation or change in dose of statin therapy
• Pregnancy

Where it is running

• NYU Langone Health — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.